Saccharomyces boulardii CNCM I‐745 modulates the microbiota–gut–brain axis in a humanized mouse model of Irritable Bowel Syndrome Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • AbstractBackgroundGnotobiotic mice colonized with microbiota from patients with irritable bowel syndrome (IBS) and comorbid anxiety (IBS+A) display gut dysfunction and anxiety‐like behavior compared to mice colonized with microbiota from healthy volunteers. Using this model, we tested the therapeutic potential of the probiotic yeast Saccharomyces boulardii strain CNCM I‐745 (S. bou) and investigated underlying mechanisms.MethodsGerm‐free Swiss Webster mice were colonized with fecal microbiota from an IBS+A patient or a healthy control (HC). Three weeks later, mice were gavaged daily with S. boulardii or placebo for two weeks. Anxiety‐like behavior (light preference and step‐down tests), gastrointestinal transit, and permeability were assessed. After sacrifice, samples were taken for gene expression by NanoString and qRT‐PCR, microbiota 16S rRNA profiling, and indole quantification.Key ResultsMice colonized with IBS+A microbiota developed faster gastrointestinal transit and anxiety‐like behavior (longer step‐down latency) compared to mice with HC microbiota. S. bou administration normalized gastrointestinal transit and anxiety‐like behavior in mice with IBS+A microbiota. Step‐down latency correlated with colonic Trpv1 expression and was associated with altered microbiota profile and increased Indole‐3‐acetic acid (IAA) levels.Conclusions & InferencesTreatment with S. bou improves gastrointestinal motility and anxiety‐like behavior in mice with IBS+A microbiota. Putative mechanisms include effects on pain pathways, direct modulation of the microbiota, and indole production by commensal bacteria.

publication date

  • March 2021

has subject area